Target intelligence / Profile preview

Complement component 3d (C3d)

Target
C3d
Molecular classification
Complement component, Opsonin, Protein fragment, Other
01

Overview

Complement component 3d (C3d) and its precursor complement component 3dg (C3dg) are stable, terminal degradation fragments of complement component 3 (C3) that are generated during the inactivation of C3b by factor I and its cofactors. Unlike upstream complement proteins that circulate freely, C3d and C3dg remain covalently attached to cell and tissue surfaces at sites of complement activation via a highly reactive thioester bond in their thioester-containing domain (TED). These fragments act as critical molecular bridges between innate and adaptive immunity by binding to complement receptor 2 (CR2/CD21) on B cells and follicular dendritic cells, thereby lowering the threshold for B-cell activation and enhancing antibody responses. They also interact with complement receptor 3 (CR3) on phagocytes to mediate cell clearance and opsonization.\n\nIn pathological states, dysregulated complement activation leads to excessive deposition of C3d and C3dg, contributing to tissue damage in autoimmune, inflammatory, and degenerative diseases, including atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), IgA nephropathy (IgAN), lupus nephritis, age-related macular degeneration (AMD), and paroxysmal nocturnal hemoglobinuria (PNH). Because C3d and C3dg are stably anchored at sites of injury, they serve as ideal homing targets for tissue-targeted therapeutics. Drugs like AKB-097 (formerly ADX-097) and TT30 utilize anti-C3d antibodies or CR2-derived targeting domains fused to complement regulators (such as factor H) to selectively inhibit the alternative complement pathway locally at the site of disease. This targeted approach aims to provide robust therapeutic efficacy while sparing systemic complement activity, thereby minimizing the systemic infection risks associated with broad complement blockade.

Other names
Complement C3d fragmentComplement C3dg fragmentComplement component 3dgC3dC3dgC3gComplement component 3gTED domain of Complement C3Thioester-containing domain of Complement C3
02

Mechanism of action

Targeted delivery of complement regulators to sites of complement activation by binding to deposited C3d/C3dg fragments, thereby locally inhibiting the alternative complement pathway and preventing downstream membrane attack complex (MAC) formation.

03

Biological functions

Immune responseOpsonizationB-cell activationComplement activationCell clearancePhagocytosisOther
04

Disease associations

InflammationAutoimmune diseaseNeurodegenerative diseaseKidney diseaseOcular diseaseParoxysmal nocturnal hemoglobinuriaOther
05

Safety considerations

Risk of infection (though significantly minimized compared to systemic complement inhibitors)Immunogenicity and development of anti-drug antibodiesTransient systemic complement suppression at high dosesTarget-mediated drug disposition due to high density of C3d/C3dg deposition
06

Interacting drugs

AKB-097 (formerly ADX-097)

4 more in the full profile.

07

Biomarkers

C3dg plasma levelsC3d tissue depositionC3dg/C3 ratioProteinuriaUrinary membrane attack complex (sC5b-9)Alternative complement pathway activity

Beyond the preview

Go deeper on Complement component 3d (C3d).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement component 3d (C3d).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call